Rifamid
|
|
|
- CAS-Nr.
- 2750-76-7
- Bezeichnung:
- Rifamid
- Englisch Name:
- rifamide
- Synonyma:
- rifamide;Rifomide;Rifamycin M-14;Rifomycin M-14;Rifampicin M/14;rifamide USP/EP/BP;Rifomycin B diethylamide;Rifamycin B diethylamide;Rifamycin, 4-O-[2-(diethylamino)-2-oxoethyl]-
- CBNumber:
- CB3908402
- Summenformel:
- C43H58N2O13
- Molgewicht:
- 810.93
- MOL-Datei:
- 2750-76-7.mol
|
Rifamid Eigenschaften
- Schmelzpunkt:
- 170°C (rough estimate)
- Siedepunkt:
- 755.63°C (rough estimate)
- alpha
- D20 -48.7° (c = 0.4 in methanol)
- Dichte
- 1.1791 (rough estimate)
- Brechungsindex
- 1.4670 (estimate)
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| Toxizit?t |
LD50 in mice, rats (mg/kg): 2450, >4000 orally; 640, 2500 s.c.; 320, 535 i.p.; 315, 380 i.v. (Dezulian) |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
|
| Sicherheit |
| P264 |
Nach Gebrauch gründlich waschen. |
| P264 |
Nach Gebrauch gründlich waschen. |
| P280 |
Schutzhandschuhe/Schutzkleidung/Augenschutz tragen. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Rifamid Chemische Eigenschaften,Einsatz,Produktion Methoden
Verwenden
Antibacterial.
Pharmazeutische Anwendungen
The diethyl amide of rifamycin B, formulated as the sodium salt for parenteral administration. It exhibits high activity against Gram-positive organisms and M. tuberculosis typical of the group. MICs for Gram-negative bacilli are of the order of 20–50 mg/L.
It is absorbed orally and is rapidly eliminated through the bile, achieving concentrations sufficient to inhibit Gramnegative bacilli. In contrast to rifampicin, it can be administered as the sodium salt by intramuscular injection. A dose of 150 mg produces mean plasma levels of about 1 mg/L. The plasma halflife is about 2 h. The same dosage produces concentrations over 1 g/L in bile and c. 40 mg/L in the gallbladder wall.
Toxicity and side effects are similar to those of other rifamycins. It has been used in staphylococcal infections and infections of the biliary tract. It is unsuitable for the treatment of tuberculosis because of insufficient distribution to the tissues.
Rifamid Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Rifamid Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 36)Lieferanten
- rifamide
- Rifamycin B diethylamide
- Rifamycin M-14
- Rifomide
- Rifomycin B diethylamide
- Rifomycin M-14
- Rifamycin, 4-O-[2-(diethylamino)-2-oxoethyl]-
- rifamide USP/EP/BP
- Rifampicin M/14
- 2750-76-7
- C43H58N2O13
